Sleeping Cancer: How Viral Infections Can Reactivate Dormant Tumors

Recent research suggests a concerning link between severe viral infections, such as influenza and COVID-19, and the reactivation of dormant cancer cells. A study published in Nature Immunology and analyzed by immunology and oncology researchers indicates that inflammation triggered by these infections can awaken “sleeping” tumor cells, potentially leading to relapse or metastasis. This discovery has implications for medical surveillance and follow-up care for cancer survivors and those at high risk.

The Phenomenon of “Sleeping Cancer”

Cancer cells can remain dormant within the body even after initial treatment appears successful. These cells, capable of traveling to distant organs like the lungs, can lie inactive for years or even decades according to research. Under specific conditions, these dormant cells can reactivate, initiating new tumor growth. The new research suggests that serious respiratory infections may act as one such trigger.

Inflammation and the Role of Interleukin-6 (IL-6)

Viral infections prompt the immune system to release cytokines, chemical messengers that coordinate the body’s defense. Interleukin-6 (IL-6), a key cytokine, increases during inflammation, particularly in respiratory infections like COVID-19. Studies suggest that elevated IL-6 levels may promote the proliferation of cancer cells as detailed in research published in PubMed.

Experiments using animal models of breast cancer with lung metastases revealed:

• Infection with the influenza virus or SARS-CoV-2 rapidly increased IL-6 levels.
• Simultaneously, the number of active tumor cells increased.
• These reactivated cells continued to multiply for months, even after IL-6 levels returned to normal, suggesting other immune mechanisms sustain the process.

The Unexpected Role of CD4+ T Cells

The study too identified a role for CD4+ T cells, a type of white blood cell that typically helps regulate the immune response. Researchers found that, CD4+ T cells appeared to protect tumor cells from attack by CD8+ T cells, which are responsible for destroying infected or cancerous cells. Eliminating CD4+ cells in the animal models led to decreased tumor proliferation, suggesting their involvement in maintaining cancer growth post-infection.

Human Data Supports the Findings

Analysis of large human medical databases, such as the UK Biobank, revealed a pattern consistent with the animal studies. Individuals in cancer remission who subsequently contracted SARS-CoV-2 had an approximately doubled risk of death from cancer in the following months as reported by Nature. Researchers at the University of Virginia also noted that severe lung infections can induce prolonged lung inflammation, creating a favorable environment for tumor growth.

What This Means for Medicine

Researchers emphasize that influenza or COVID-19 do not directly cause cancer. Instead, the study suggests that in individuals with pre-existing latent tumor cells, the inflammation triggered by severe infections can activate their growth.

This discovery has several potential medical implications:

• Increased medical surveillance for individuals who have experienced severe respiratory infections.
• Enhanced oncological follow-up for patients with a history of cancer.
• Potential exploration of drugs that block IL-6 in high-risk patients.
• Reinforcement of vaccination strategies against influenza and COVID-19.

Vaccines may reduce the immunological changes that promote tumor growth in the lungs.

Ongoing Research and Future Directions

Scientists acknowledge that many questions remain. Further research is needed to determine:

• Whether other respiratory viruses have similar effects.
• If the phenomenon occurs in other cancer types or organs.
• How to prevent tumor reactivation without compromising the body’s defense against infections.

This discovery connects viral infections and metastatic cancer, two areas often studied independently. Continued research promises to develop new prevention and monitoring strategies for millions of patients worldwide.